All In Biotech

Investigational drug · Phase 3

Test drug CB03-154 group

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for ALS (Amyotrophic Lateral Sclerosis), Focal Epilepsy.

Phase 3

Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

2

Any phase or sponsor naming "Test drug CB03-154 group"

First trial start

2024

Aug 14, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Test drug CB03-154 group", any sponsor or status.

Conditions studied

As listed on its trial records.

  • ALS (Amyotrophic Lateral Sclerosis)
  • Focal Epilepsy

Approved drugs for the same conditions: Epilepsy and seizures · ALS (amyotrophic lateral sclerosis) · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "Test drug CB03-154 group" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for ALS (Amyotrophic Lateral Sclerosis)

  • Foralumab NasalPhase 22 trials

    Tiziana Life Sciences LTD · ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis, ALS

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.